Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunomodulation by paracrine signaling refers to the regulation of immune cell behavior through the secretion of soluble factors (paracrine factors), such as cytokines, chemokines, and extracellular vesicles, by cells like mesenchymal stem/stromal cells (MSCs) or other tissue-resident cells. These paracrine mediators act locally on neighboring immune and stromal cells to influence immune responses, typically suppressing inflammation, promoting regulatory phenotypes, or facilitating tissue repair[1][5][3][2]. The process involves multiple well-characterized molecules (e.g., IL-10, TGF-β, IDO, PGE2, HGF) and their corresponding receptors. However, 'immunomodulation by paracrine signaling' itself is not a discrete molecular target, but a complex biological phenomenon underlying the actions of various cell therapies and regenerative interventions[3][5][7][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunomodulation by paracrine signaling.